Adam Walsh
Stock Analyst at Roth Capital
(2.64)
# 1,959
Out of 5,154 analysts
14
Total ratings
66.67%
Success rate
14.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Initiates: Buy | $212 | $140.13 | +51.29% | 1 | Jan 23, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $58 | $35.22 | +64.68% | 1 | Jan 23, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $146 → $171 | $240.65 | -28.94% | 3 | Apr 20, 2020 | |
| GLPG Galapagos NV | Maintains: Buy | $121 → $188 | $32.92 | +471.08% | 4 | Jul 15, 2019 | |
| CORT Corcept Therapeutics | Downgrades: Hold | n/a | $33.87 | - | 4 | May 31, 2018 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $74 → $77 | $21.25 | +262.35% | 1 | Apr 18, 2018 |
Insmed
Jan 23, 2026
Initiates: Buy
Price Target: $212
Current: $140.13
Upside: +51.29%
vTv Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $58
Current: $35.22
Upside: +64.68%
Ascendis Pharma
Apr 20, 2020
Maintains: Buy
Price Target: $146 → $171
Current: $240.65
Upside: -28.94%
Galapagos NV
Jul 15, 2019
Maintains: Buy
Price Target: $121 → $188
Current: $32.92
Upside: +471.08%
Corcept Therapeutics
May 31, 2018
Downgrades: Hold
Price Target: n/a
Current: $33.87
Upside: -
Ultragenyx Pharmaceutical
Apr 18, 2018
Maintains: Buy
Price Target: $74 → $77
Current: $21.25
Upside: +262.35%